Jun 1 2011 | 4:49am ET
The Securities and Exchange Commission is zeroing in on SAC Capital Advisors in its investigation into possible insider trading of healthcare stocks.
SAC is the focus of a probe into trading around AstraZeneca's 2007 takeover of biotechnology firm MedImmune Inc. It is the third insider-trading investigation of the $14 billion hedge fund giant to emerge in recent months.
Mar 10 2014 | 11:33am ET
A huge thank you to all of the people who helped make last Thursday’s HFC NY Open Your Heart to the Children Benefit such a success. The charity gala raised nearly $2 million to prevent and treat child abuse in New York, New Jersey and Connecticut. Read more…